BARDA highlights Tiba in a new FASTx program to accelerate the development of early-stage antiviral platforms with multiple collaborators
BARDA highlights Tiba in a new FASTx program to accelerate the development of early-stage antiviral platforms with multiple collaborators
Tiba’s co-founder and mRNA visionary, Christian Mandl, spoke at the Global Vaccine and Immunization Research Forum 2021, the central forum for research related to the Immunization Agenda 2030 (IA2030). GVIRF is the only global meeting that brings together the entire Vaccine and Immunization Research community, from basic immunology to implementation research, and from low to high income countries.